A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Ali Al-Zuhairy, b Department of Neurology , Copenhagen University Hospital, Rigshospitalet , Copenhagen , Denmark.
  • ,
  • Søren H Sindrup, Department of Neurology, Odense University Hospital, Odense, Denmark.
  • ,
  • Henning Andersen
  • Johannes Jakobsen, b Department of Neurology , Copenhagen University Hospital, Rigshospitalet , Copenhagen , Denmark.
Introduction
The effect of long‐lasting immune‐modulating therapy was studied in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Methods
A population‐based cross‐sectional study of treated patients referred to the Danish healthcare system between 1985 and 2006.

Results
The 51 participating patients had a median disease duration of 16 years (inter quartile range: 14 – 21). Twenty‐seven (53%) had discontinued therapy and 46 walked independently. Disability and isokinetic strength were impaired by 17% and 20%, respectively, as compared to matched control subjects. For a few patients long‐term CIDP was associated with severe morbidity (6%) and even mortality (1%). Prolongation of time until start of therapy was associated with an increased burden of long‐term disability.

Discussion
Long‐term prognosis in treated CIDP is characterized by limited disability in the majority of patients. Disability is related to delay of therapy. Therefore, more attention should be given to early treatment start in CIDP.

This article is protected by copyright. All rights reserved.
OriginalsprogEngelsk
TidsskriftMuscle & Nerve
Vol/bind61
Nummer3
Sider (fra-til)316-324
Antal sider9
ISSN0148-639X
DOI
StatusUdgivet - 2020

Bibliografisk note

This article is protected by copyright. All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 173218751